FDA Panel Votes To Limit ESA Cancer Use To Metastatic Patients
Executive Summary
Following the recommendations of its Oncologic Drugs Advisory Committee, FDA's next step in ensuring the safe use of erythropoiesis-stimulating agents will be to determine how best to narrow the approved indication for anemia treatment in the cancer setting